In this interview, Adam Hill, CEO of Oncimmune #ONC – a global immunodiagnostics firm with a leading position in autoimmune profiling – explains:
00:00 How the ImmunoINSIGHTS platform is typically used
03:35 Strategy of developing preferred supplier agreements with the world’s top BioPharmas
06:15 The division’s H1 performance & expected growth trajectory for the rest of the year
12:20 Possible M&A opportunities
13:45 Does the group need to consider strengthening its balance sheet?
14:40 Update on the EarlyCDT lung cancer test
16:50 Why is the yearend being changed from May to Aug?
18:25 Future newsflow
19:20 Typical contract values/duration
20:25 Size of orderbook